{"id":"W2737383904","doi":"10.1182/blood-2017-05-784678","title":"Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma","year":2017,"lang":"en","type":"letter","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; BC Cancer Agency","keywords":"Brentuximab vedotin; ABVD; Dacarbazine; Medicine; Oncology; Vinblastine; Internal medicine; Classical Hodgkin lymphoma; Lymphoma; Stage (stratigraphy); Bleomycin; Hodgkin lymphoma; Chemotherapy; Vincristine; Cyclophosphamide; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000551035,0.0001867505,0.0007416833,0.0003351906,0.0008253668,0.0006201539,0.0004966325,0.002475426,0.001779275],"category_scores_gemma":[0.003986318,0.0001884266,0.0008188905,0.000582466,0.0003088217,0.0007622692,0.000251821,0.002814241,0.0005431833],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001189478,"about_ca_system_score_gemma":0.0006230429,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004229338,"about_ca_topic_score_gemma":0.005168087,"domain_scores_codex":[0.9994733,0.0001191315,0.00005561664,0.0000633223,0.0001204595,0.0001682306],"domain_scores_gemma":[0.9978987,0.0008936194,0.000294878,0.0001114539,0.0003596766,0.0004416406],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"case_report","study_design_gemma":"observational","study_design_scores_codex":[0.01074665,0.001242667,0.3639483,0.0002133353,0.0007357362,0.3933078,0.001049025,0.00221641,0.003993765,0.001279294,0.08529767,0.1359695],"study_design_scores_gemma":[0.001572334,0.007200379,0.6077825,0.0006036185,0.002188097,0.2869453,0.001720825,0.007256257,0.002092149,0.00494579,0.07746752,0.0002252453],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8434547,0.02043697,0.001674216,0.104179,0.004405375,0.0001082583,0.001568227,0.0001188777,0.02405435],"genre_scores_gemma":[0.9760919,0.001568374,0.0002406168,0.01622532,0.002063885,0.000018434,0.0007237587,0.00001562946,0.003052129],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004229338,"threshold_uncertainty_score":0.008630335,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01968499113086506,"score_gpt":0.2696222013668995,"score_spread":0.2499372102360344,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}